Overview

COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg

Status:
Completed
Trial end date:
2020-06-07
Target enrollment:
Participant gender:
Summary
The comparator drug (Zoladex 3.6 mg) is approved for use as a thinning agent for the endometrium prior to endometrial ablation. The dosing recommendation is one or two depots with each depot given four weeks apart. When two depots are administered, surgery should be performed within two to four weeks following administration of the second depot.
Phase:
Phase 1
Details
Lead Sponsor:
Peptigroupe Inc.
Treatments:
Goserelin